Dublin, Sept. 27, 2024 (GLOBE NEWSWIRE) -- The "Diabetes Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Diabetes Drugs was estimated at US$110.4 Billion in 2023 and is projected to reach US$205.3 Billion by 2030, growing at a CAGR of 9.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. 
Recent advancements have introduced drugs that mimic intestinal hormones to slow digestion and sugar absorption. Each medication is tailored to fit the patient's specific health profile, with the goal of maintaining blood glucose levels within a normal range, thus preventing the long-term complications of diabetes, such as heart disease, kidney damage, and vision loss.
What Drives the Growing Market for Diabetes Drugs?
The growth in the diabetes drugs market is driven by several factors, including the rising global prevalence of diabetes due to increasing obesity rates, aging populations, and higher incidences of sedentary lifestyles. Advances in drug research and development, resulting in more efficacious and safer medications, also boost the market growth. Additionally, there is a growing awareness and better screening for diabetes, leading to earlier and increased diagnosis and treatment of the disease.
Economic development and the expansion of healthcare infrastructure in emerging markets provide access to medical care for a larger portion of the population, further expanding the demand for diabetes medications. The increasing adoption of digital health solutions for disease management and the expansion of personalized medicine are also crucial factors contributing to the robust growth of this market. Together, these dynamics ensure sustained investment and innovation within the sector, responding to the urgent need for effective diabetes management solutions.
How Has Innovation Influenced the Development of Diabetes Medications?
Innovation in diabetes treatment has seen substantial growth over the past few decades, driven by a deeper understanding of the disease and its metabolic pathways. Modern drug development has introduced several new classes of medications, including GLP-1 receptor agonists and SGLT2 inhibitors, which have changed the diabetes treatment paradigm.
GLP-1 receptor agonists, such as exenatide and liraglutide, enhance insulin secretion and suppress glucagon release in a glucose-dependent manner, offering benefits beyond glycemic control, such as weight loss and cardiovascular risk reduction. SGLT2 inhibitors reduce blood glucose by preventing the kidneys from reabsorbing glucose back into the blood. Moreover, the advent of biosimilars and improvements in insulin therapy, including faster-acting insulins and insulin analogs, provide more physiological and convenient treatment options, enhancing patient adherence and overall quality of life.
What Role Does Personalized Medicine Play in Diabetes Care?
The shift towards personalized medicine in diabetes care is a game-changer, enhancing the efficacy and safety of treatment protocols. Personalized medicine in diabetes involves tailoring drug therapies based on an individual's genetic makeup, lifestyle, and specific health needs. This approach not only helps in selecting the most effective medication for each patient but also in determining the optimal dose and timing of administration to minimize side effects and maximize benefits.
For instance, the choice between using a standard drug regimen versus newer agents may depend on factors such as a patient's cardiovascular health, kidney function, and potential for hypoglycemic episodes. Personalized medicine has been facilitated by advances in genetic testing and mobile health technologies, which allow for continuous monitoring of blood glucose levels and real-time data analysis. This personalization helps in predicting disease progression and in making more informed decisions regarding adjustments in therapy, thereby significantly improving patient outcomes.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Insulin segment, which is expected to reach US$123.1 Billion by 2030 with a CAGR of a 8.5%. The Non-Insulin Drugs segment is also set to grow at 10.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, which was estimated at $28.8 Billion in 2023, and China, forecasted to grow at an impressive 12.4% CAGR to reach $46.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 196 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $110.4 Billion |
| Forecasted Market Value (USD) by 2030 | $205.3 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Diabetes Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
MARKET TRENDS & DRIVERS
- Rising Global Prevalence of Diabetes Spurs Continuous Demand for Medications
- Advances in Insulin Delivery Systems Propel Market Innovation
- Development of GLP-1 Receptor Agonists Expands Treatment Options
- Integration of Digital Health Technology in Diabetes Management Enhances Patient Compliance
- Pharmaceutical Innovations and Pipeline Expansions Set the Stage for New Therapies
- Growing Awareness of Diabetes Symptoms and Management Drives Market Education
- Health Insurance Expansion and Access to Medication Improve Patient Outcomes
- Competitive Landscape Shaped by Patent Expiries and Biosimilars
- Technological Advancements in Continuous Glucose Monitoring (CGM) Systems
FOCUS ON SELECT PLAYERS(Total 46 Featured)
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Sanofi
- Takeda Pharmaceuticals Company Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/vw7nvy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
